Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

d, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)

are trademarks of Tissue Repair Company. InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),

RapidBlue(TM
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 According to a new ... (HPLC, UHPLC, Flash), GC, Other Components (Autosamplers, Detectors, Fraction ... - Analysis & Global Forecasts to 2020", published by ... around 9.223 Billion by 2020 from USD 7.062 Billion ... Browse 141 tables and 36 figures spread through 277 ...
(Date:9/3/2015)... ... , ... If you plan to attend the 27th annual Tradeline College ... to sign up for the tour of Framingham State University's newest addition to Hemenway ... of the (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume ...
(Date:9/2/2015)... , ... September 02, 2015 ... ... of regulatory compliance, quality systems, analytical testing, education and consulting services for ... expertise in medical device products/processes development, design control, validation, quality assurance and ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... and managed with the use of special anti-vascular endothelial growth factor agents given ... more patients, currently does not have a scientific protocol for the many millions ...
Breaking Biology Technology:Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... Patent 7,300,650 entitled "Reovirus for the Treatment of ... to treat cancers that,have inactivated PKR, whether the ... other factors. PKR is a host cellular protein ...
... Xenome Ltd, a specialist,biopharmaceutical company developing ... successfully raised US$10M of equity finance. The ... major investor,Queensland BioCapital Funds (QBF), for $2.7M, ... Inc, a top tier USA biotechnology company,headquartered ...
... Geffen School of Medicine at UCLA and the Howard ... largest cellular particle ever crystallized, suggesting ways to engineer ... The research study, which focuses on new engineered nanomaterial ... the Nov. 27 edition of the peer-reviewed, open-access journal ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 3Researchers outline structure of largest nonvirus particle ever crystallized 2
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... The American College of Preventive Medicine (ACPM) ... literature review on lifestyle medicine the practice of ... and treat disease. The document summarizes scientific ... information on related topics such as definitions, reimbursement ...
... Carolina State University researcher has devised a new technology ... be the key to eliminating foul odors and air ... ultimately large-scale swine feedlots. Dr. Praveen Kolar, ... State, has developed an inexpensive treatment process that significantly ...
... A new study from NYU School of Medicine found that ... in the thirty days following an acute coronary syndrome (ACS), but ... severity and type of ACS. The study, published in the August ... Association ( JAMA ), found however that overall there was ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2This idea doesn't stink: New tech cuts industrial odors, pollutants 2Study finds women slightly more likely to die than men in the 30 days following a heart attack 2
Protein Tyrosine Phosphatase Sampler Kit 10g each...
SH3 Proteins II Sampler Kit 10g each...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Golgi Sampler Kit 10g each...
Biology Products: